CTRI/2021/06/034065尚未招募未知
Cardiovascular disease manifestations with special emphasis on myocarditis-in moderate to severe COVID-19 patients undergoing treatment in the ccu of a tertiary care hospital in West Bengal India
Dr Swati Datta0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Age more than 18 years
- •2. Laboratory confirmed COVID-19 patients
- •3. SpO2 less than 94%
- •4. Patients on different modalities of oxygen therapy
- •5. Patients with radiologically confirmed pneumonia
- •6. ARDS or Acute Respiratory Failure
- •1. Age more than 18 years
- •2. COVID-19 RTPCR negative
- •3. SpO2 less than 94%
- •4. Patients on different modalities of oxygen therapy
- •5. Patients with radiologically confirmed pneumonia
- •6. ARDS or Acute Respiratory Failure
排除标准
- •1. Moribund patient with septicemia with or without multiorgan dysfunction
- •2. Patient unwilling to participate in the study
研究者
相似试验
已完成
不适用
Cardiac- and vascular disease (-abnormalities) as underlying cause of premature birth.premature birth100103941001027310003216NL-OMON39237Academisch Medisch Centrum300
尚未招募
不适用
Cardiac Effects In Moderate ToSevere COVID-19 Patients Receiving Treatment InCritical Care Unit Of A Tertiary Care Hospital,West BengalCTRI/2021/06/034469MEDICAL COLLEGE KOLKATA
已完成
不适用
Delivering enhanced cardiovascular disease and hypertension care through private health facilities in PakistaHypertension / Cardiovascular DiseaseCirculatory SystemAtherosclerotic cardiovascular diseaseISRCTN34381594niversity of Leeds (UK)912
已完成
不适用
Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI).End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)JPRN-UMIN000000492agoya University160
招募中
3 期
ong term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Cardiovascular - Normal development and function of the cardiovascular systemMetabolic and Endocrine - DiabetesACTRN12607000333415Consorzio Mario Negri Sud2,100